利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.03 秒)

    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
    5.
    发明申请
    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF 有权

    公开(公告)号：US20210139578A1

    公开(公告)日：2021-05-13

    申请号：US17023927

    申请日：2020-09-17

    申请人： THE TRUSTEES OF DARTMOUTH COLLEGE

    发明人： Randolph J. NOELLE ,  Lili WANG

    IPC分类号： C07K16/28 ,  C07K14/705

    摘要： The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and artritic conditions such as RA.

    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
    6.
    发明公开
    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF 审中-公开

    公开(公告)号：US20240132586A1

    公开(公告)日：2024-04-25

    申请号：US18476403

    申请日：2023-09-27

    申请人： THE TRUSTEES OF DARTMOUTH COLLEGE

    发明人： Randolph J. NOELLE ,  Lili WANG

    IPC分类号： C07K16/28 ,  C07K14/705

    CPC分类号： C07K16/28 ,  C07K14/70503 ,  C07K16/2803 ,  A61K2039/505

    摘要： The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and arthritic conditions such as RA.

    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
    7.
    发明公开
    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF 审中-公开

    公开(公告)号：US20240228609A9

    公开(公告)日：2024-07-11

    申请号：US18476403

    申请日：2023-09-28

    申请人： THE TRUSTEES OF DARTMOUTH COLLEGE

    发明人： Randolph J. NOELLE ,  Lili WANG

    IPC分类号： C07K16/28 ,  C07K14/705

    CPC分类号： C07K16/28 ,  C07K14/70503 ,  C07K16/2803 ,  A61K2039/505

    摘要： The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and arthritic conditions such as RA.

    Regulatory T Cell Mediator Proteins and Uses Thereof
    9.
    发明申请
    Regulatory T Cell Mediator Proteins and Uses Thereof 审中-公开
    调节性T细胞介导蛋白及其用途

    公开(公告)号：US20160168248A1

    公开(公告)日：2016-06-16

    申请号：US14940940

    申请日：2015-11-13

    申请人： The Trustees of Dartmouth College

    发明人： Randolph J. NOELLE ,  Li Wang

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70596 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/505 ,  Y02A50/412 ,  Y02A50/423

    摘要： The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed

    摘要翻译： 本发明涉及新型调节性T细胞蛋白。 称为PD-L3的一种蛋白质类似于PD-L1家族的成员，并且在体外共同刺激T细胞的αCD3增殖。 第二种TNF样蛋白也被鉴定为在αCD3/αGITR刺激下上调。 该蛋白质已被命名为Treg-sTNF。 公开了蛋白质，抗体，活化的T细胞和使用它们的方法。 特别是使用这些蛋白质和化合物（优选抗体）的方法，其结合或调节（激动或拮抗）这些蛋白质的活性，作为免疫调节剂和用于治疗癌症，自身免疫疾病，变态反应，感染和炎性病症，例如， 公开了多发性硬化